Septerna (NASDAQ:SEPN) Shares Up 8.5% - Should You Buy?

Key Points

• Septerna, Inc. (NASDAQ:SEPN) shares increased by 8.5% to close at $22.80, despite an 80% decline in trading volume compared to its average.
• Wall Street analysts maintain a Moderate Buy consensus for Septerna, with price targets ranging from $25.00 to $26.75, while one firm downgraded the stock to a "Hold" rating.
• Septerna's recent earnings report revealed a loss of ($0.56) per share, significantly missing analysts' expectations, and the company is projected to post a -7.11 EPS for the current year.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) shares shot up 8.5% on Wednesday . The stock traded as high as $22.69 and last traded at $22.80. 124,566 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 609,475 shares. The stock had previously closed at $21.01.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Septerna in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and set a $26.00 price objective on shares of Septerna in a research note on Thursday, August 21st. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of Septerna in a research note on Friday, September 5th. Finally, Wall Street Zen upgraded shares of Septerna from a "sell" rating to a "hold" rating in a research note on Sunday, September 21st. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Price Performance

The stock's fifty day moving average is $14.19 and its 200-day moving average is $10.75. The stock has a market capitalization of $1.01 billion and a PE ratio of -2.23.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. On average, analysts forecast that Septerna, Inc. will post -7.11 EPS for the current year.

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of SEPN. KLP Kapitalforvaltning AS purchased a new position in shares of Septerna in the first quarter worth about $49,000. Chicago Partners Investment Group LLC purchased a new position in shares of Septerna in the first quarter worth about $63,000. Deutsche Bank AG lifted its stake in shares of Septerna by 53.3% in the first quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock worth $92,000 after buying an additional 5,549 shares in the last quarter. Stoneridge Investment Partners LLC purchased a new position in shares of Septerna in the first quarter worth about $107,000. Finally, PharVision Advisers LLC purchased a new position in shares of Septerna in the second quarter worth about $107,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.